# Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

> **NCT05855200** · PHASE3 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 892 (estimated)

## Conditions studied

- Colonic Neoplasms
- Neoplasms, Colon

## Interventions

- **BIOLOGICAL:** Dostarlimab
- **DRUG:** CAPEOX
- **DRUG:** FOLFOX

## Key facts

- **NCT ID:** NCT05855200
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-01
- **Primary completion:** 2029-03-19
- **Final completion:** 2031-03-27
- **Target enrollment:** 892 (ESTIMATED)
- **Last updated:** 2026-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05855200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05855200, "Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05855200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*